The aim of the study was to review existing recommendations on study design, conduct, analysis, and reporting for primary studies of therapeutic medical devices (TMDs) and the closely related field of interventional procedures.
These advancements have included recommendations on study design including subject selection strategies and sample size to uncover elements of varying frequency and effect sizes.
The DMC gave recommendations on study conduct after the review of the extensive report about the interim analysis including data on patient recruitment, baseline characteristics, eligibility violations, treatment compliance, compliance with planned visits, completeness of follow-up, and safety separately for the different treatment arms.
8 9 Furthermore, our review did not base recommendations on studies deemed to have a low quality of evidence.
Guidelines in favor of probiotics (CCH, ESP and NHG) base their recommendations on studies with positive outcomes for different species of probiotics.
Both guidelines base these recommendations on studies performed in secondary and tertiary care, which may not be applicable for primary care settings.
This has considerable implications for clinical practice, but is not yet included in clinical guidelines (2, 3); most current clinical guidelines base their recommendations on studies performed using assays which are outdated by approximately a decade.
It based its recommendation on a study of 1,639 heart-attack patients in Europe, Canada and the United States.
However, as noted above, that recommendation was based on one study of Latin America of the effects of IPIs following induced or spontaneous abortions.
They base their recommendation on simulation studies in which they evaluate the precision of an effect estimate under various dose response models.
